CME
HOME SITEMAP REGISTRATION FEEDBACK ALL COURSES MY CME

Application of PET/CT in the Development of Novel Anticancer Drugs

TEST_code
CME Activity Information
Release Date: February 1, 2008
Most Recent Review: February 1, 2008*
Most Recent Update: February 1, 2008
Date Credit Expires: February 1, 2010
Time to Complete: 1 hour
Medium: Internet Online
*Click here to learn more about our review process.
Instructions for Participation

  1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
  2. Study the educational activity
  3. Complete the CME quiz and evaluation
  4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

    *The CME quiz and evaluation must be completed by February 1, 2010, in order to receive the credit or participation certificate.

 

Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine in clincial pharmacology and are involved in providing patient care in a cancer care environment.

Learning Objectives
After completing this course, the reader should be able to:
  1. Describe the advantages of combined PET/CT over single PET and single CT imaging.
  2. Mention the applications of combined PET/CT in the evaluation of novel anticancer drugs.
  3. Describe which radiotracers are used for pharmacokinetic and pharmacodynamic measurements in anticancer drug development.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the School of Medicine of The University of North Carolina at Chapel Hill and The Oncologist. The School of Medicine of The University of North Carolina at Chapel Hill is accredited by the ACCME to provide continuing medical education for physicians.

The School of Medicine of The University of North Carolina at Chapel Hill designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the School of Medicine of The University of North Carolina at Chapel Hill to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Content Review
The content of this manuscript has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Author Disclosure(s)
David S. Boss, M.D.

Credentials: Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of various PET tracers for PET imaging, diagnosis, response, pharmacokinetics, and pharmacodynamics. The author has indicated no relevant commercial relationships.

Renato Valdes Olmos, M.D.

Credentials: Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of various PET tracers for PET imaging, diagnosis, response, pharmacokinetics, and pharmacodynamics. The author has indicated no relevant commercial relationships.

Michiel Sinaasappel, M.D.

Credentials: Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of various PET tracers for PET imaging, diagnosis, response, pharmacokinetics, and pharmacodynamics. The author has indicated no relevant commercial relationships.

Jos H. Beijnen, M.D.

Credentials: Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of various PET tracers for PET imaging, diagnosis, response, pharmacokinetics, and pharmacodynamics. The author has indicated no relevant commercial relationships.

Jan H. M. Schellens, M.D., Ph.D.

Credentials: Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Section of Biomedical Analysis, Division of Drug Toxicology, Utrecht, The Netherlands. Telephone: 31-20-512-2569; Fax: 31-20-512-2572; E-mail: jhm{at}nki.nl.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of various PET tracers for PET imaging, diagnosis, response, pharmacokinetics, and pharmacodynamics. The author has indicated no relevant commercial relationships.

Section Editors Disclosures
O.S. Hoekstra, M.D., Ph.D., and Malik Juweid, M.D., have disclosed no financial relationships relevant to the content of this article.

CME Activity Director Disclosure
Frank M. Balis, M.D., CME Activity Director, has disclosed no financial relationships relevant to the content of this article.

Independent Peer Reviewers and Staff Managers Disclosures
No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or staff managers.

Commercial Support
Non-governmental supporters of this activity: Abraxis BioScience, AstraZeneca, Bristol-Myers Squibb Oncology, Merck, Pfizer, and sanofi-aventis

Hardware/Software Requirements
The Oncologist CME Online supports the following browsers: Current production versions of Opera, Safari, Firefox, Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh version of Explorer was discontinued in June 2003, and is not supported.

Other Links
Disclaimer
Privacy statement

Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu

HOME SITEMAP REGISTRATION FEEDBACK ALL COURSES MY CME
Copyright © 2008 by AlphaMed Press.